Atreca is reorganizing the company’s workforce in a bid to extend its cash reserves to 2023.
Posts
Shares of Repare Therapeutics soared more than 27 percent in premarket trading on June 2 following the previous day’s announcement of a global cancer collaboration valued at up to $1.2 billion with Swiss pharma giant Roche for the development and commercialization of camonsertib.
Servier today announced that the U.S. Food and Drug Administration approved TIBSOVO (ivosidenib tablets) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) are combining their efforts to increase racial and ethnic diversity in clinical trials.
Imugene and City of Hope announced this week that the first patient has begun treatment in a revolutionary Phase I clinical trial, investigating the safety and efficacy of CF33-hNIS (Vaxinia), a cancer-killing virus, in adults with metastatic or advanced tumors.
March 14 marks the launch of Lumanity, a company dedicated to improving patient health by accelerating and optimizing access to medical advances.
There was a significant drop-off in NME approvals by FDA in 2016, but there were not enough new drug applications with user fee goals to reach the lofty 2015 total.
The U.S. biotechnology arena is undergoing a record-breaking M&A cycle for the industry. After generating M&A activity valued at $235 billion during 2014, the U.S. biotech sector produced more than $100 billion in deals during first-quarter 2015.
FDA Grants Genentech’s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Announcement Follows FDA Breakthrough Therapy Designation for GA101 in CLL FDA Decision on the GA101 Biologics […]
